Literature DB >> 16372227

Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.

M Schott1, W B Minich, H S Willenberg, C Papewalis, J Seissler, J Feldkamp, A Bergmann, W A Scherbaum, N G Morgenthaler.   

Abstract

Recently, we demonstrated that higher levels of autoantibodies to the human TSH receptor (TBII) predict relapse of hyperthyroidism in Graves' disease (GD). The aim of this study was to extend this outcome prediction by dividing TBII into stimulating (TSAb) and blocking (TBAb) TSH receptor autoantibodies. Altogether, ninety patients (81 female, 9 male) were retrospectively analyzed; sixty-four patients (71 %) did not go into remission or relapsed, whereas twenty-six patients (29 %) went into remission (median follow-up: 17.5 months). TSAb and TBAb measurement was performed in a CHO cell bioassay with cAMP readout at the time of their first visit in our outpatient clinic (single point measurement in median 6.5 months after initial diagnosis). In the remission group, eighteen of twenty-six patients (69 %) were TSAb-positive, whereas fifty-three of sixty-four patients (83 %) were TSAb-positive in the relapse group (p = ns). The mean stimulation indices (SI) were 4.1 in the remission group and 12.9 in the relapse group, respectively (p = 0.015). By using a threshold of 10 SI, the specificity for relapse was 96.0 %, as only one in twenty patients with an SI above 10 went into remission during follow-up (PPV 95 %). Most TSAb-positive patients also had high levels of TBII. Neither group showed any difference with respect to blocking type autoantibodies, which were mostly negative in both groups. In summary, high TSAb levels are similar but not superior to TBII for predicting relapse in GD patients. In contrast, TBAb measurement does not add any valuable information in this context. In the clinical routine, TSAb/TBAb measurement may not play an important role for diagnosis or outcome prediction of GD, since sensitive 2 (nd) generation TBII assays are easier to perform and offer similar information to the clinician. Bioassays should be reserved for special clinical questions such as Graves' disease in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16372227     DOI: 10.1055/s-2005-921099

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  7 in total

1.  Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins.

Authors:  S D Lytton; Y Li; P D Olivo; L D Kohn; G J Kahaly
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

2.  Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.

Authors:  E Mazza; M Carlini; D Flecchia; A Blatto; O Zuccarini; S Gamba; S Beninati; M Messina
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

3.  Bioassays for TSH Receptor Antibodies: Quo Vadis?

Authors:  George J Kahaly
Journal:  Eur Thyroid J       Date:  2015-03

4.  Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.

Authors:  S Seo; M Sánchez Robledo
Journal:  J Endocrinol Invest       Date:  2018-09-07       Impact factor: 4.256

5.  Interleukin-21 is associated with disease activity in patients with Graves' disease.

Authors:  Jin Zhang; Hua Zeng; Meng Ren; Haiyan Yan; Mingtong Xu; Zhimei Feng; Weiwen Liang; Chuan Yang; Hua Cheng; Helin Ding; Li Yan
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

6.  Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease.

Authors:  Hyemi Kwon; Won Gu Kim; Eun Kyung Jang; Mijin Kim; Suyeon Park; Min Ji Jeon; Tae Yong Kim; Jin Sook Ryu; Young Kee Shong; Won Bae Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2016-04-25

7.  Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.

Authors:  George J Kahaly; Tanja Diana; Michael Kanitz; Lara Frommer; Paul D Olivo
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.